跳转至内容
Merck
CN
  • Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins

Applying valency-based immuno-selection to generate broadly cross-reactive antibodies against influenza hemagglutinins

Nature Communications (2024)
Daniela M, et al.